CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), specifically those targeting the PD-1/PD-L1 axis, have emerged as first-line treatments for advanced non-small cell lung cancer (NSCLC)2,3 as well as lung metastases of different origins, such as skin, colorectal, breast or renal cell carcinoma4–6.